JP2005075834A - 神経変性疾患の処置 - Google Patents

神経変性疾患の処置 Download PDF

Info

Publication number
JP2005075834A
JP2005075834A JP2004256724A JP2004256724A JP2005075834A JP 2005075834 A JP2005075834 A JP 2005075834A JP 2004256724 A JP2004256724 A JP 2004256724A JP 2004256724 A JP2004256724 A JP 2004256724A JP 2005075834 A JP2005075834 A JP 2005075834A
Authority
JP
Japan
Prior art keywords
phenyl
substituted
furyl
disease
indazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004256724A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005075834A5 (https=
Inventor
Wen-Mei Fu
フ ウェン−メイ
Houng-Chi Liou
リュウ フォン−チ
Dah-Yuu Lu
ルー ダー−ユウ
Che-Ming Teng
テン チェ−ミン
Sheng-Chu Kuo
クオ シェン−チュ
Fang-Yu Lee
リー ファン−ユ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carlsbad Technology Inc
Original Assignee
Carlsbad Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carlsbad Technology Inc filed Critical Carlsbad Technology Inc
Publication of JP2005075834A publication Critical patent/JP2005075834A/ja
Publication of JP2005075834A5 publication Critical patent/JP2005075834A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2004256724A 2003-09-03 2004-09-03 神経変性疾患の処置 Pending JP2005075834A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/653,859 US20040077702A1 (en) 2001-09-14 2003-09-03 Treatment of nuerodegenerative diseases

Publications (2)

Publication Number Publication Date
JP2005075834A true JP2005075834A (ja) 2005-03-24
JP2005075834A5 JP2005075834A5 (https=) 2007-10-18

Family

ID=34136658

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004256724A Pending JP2005075834A (ja) 2003-09-03 2004-09-03 神経変性疾患の処置

Country Status (8)

Country Link
US (1) US20040077702A1 (https=)
EP (1) EP1512400B1 (https=)
JP (1) JP2005075834A (https=)
KR (1) KR20050024272A (https=)
CN (1) CN1626077A (https=)
AT (1) ATE460161T1 (https=)
DE (1) DE602004025885D1 (https=)
TW (1) TW200510329A (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004275694B2 (en) 2003-06-30 2008-03-06 Bizbiotech Co., Ltd. Compounds, compositions and methods
US20080200557A1 (en) * 2004-07-07 2008-08-21 Caritas St. Elizabeth Hospital Of Boston, Inc. Method for Inhibiting Lipid Peroxidation
US20080252028A1 (en) * 2007-04-16 2008-10-16 Ming-Tai Huang Shock absorbing device for toy stroller
WO2008136772A1 (en) * 2007-05-02 2008-11-13 Agency For Science, Technology And Research Method of monitoring retinopathy
US20140163082A1 (en) 2011-05-06 2014-06-12 King Khalid Eye Specialist Hospital Pyrazolyl compounds for use in reversing reactive gliosis

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11302277A (ja) * 1997-10-06 1999-11-02 Hoechst Marion Roussel Deutsche Gmbh ピラゾール誘導体、その製法および医薬としてのその使用
JP2001502318A (ja) * 1996-10-14 2001-02-20 バイエル・アクチエンゲゼルシヤフト 心臓血管系および中枢神経系の特定疾病を治療するための縮合（ヘタリール置換）１―ベンジル―３―ピラゾール誘導体の使用
WO2001016359A2 (en) * 1999-08-31 2001-03-08 University College London Screen for axon viability
WO2001049275A2 (en) * 1999-12-29 2001-07-12 Queen's University At Kingston Methods and compositions for mitigating pain using nitrate esters
WO2002010137A2 (en) * 2000-07-31 2002-02-07 Signal Pharmaceuticals, Inc. Indazole derivatives as jnk inhibitors
WO2002083648A1 (fr) * 2001-04-16 2002-10-24 Eisai Co., Ltd. Nouveau compose a base de 1h-indazole
WO2003024397A2 (en) * 2001-09-14 2003-03-27 Carlsbad Technology, Inc. Enhancement of learning and memory and treatment of amnesia
WO2003068754A1 (en) * 2002-02-13 2003-08-21 Astrazeneca Ab Therapeutic substituted indazole derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US105149A (en) * 1870-07-05 Egbert l
US4355A (en) * 1846-01-15 Beehive
JP2928079B2 (ja) * 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
US5760230A (en) * 1996-10-11 1998-06-02 Bayer Aktiengesellschaft 4, 4'-bridged bis-2, 4-diaminoquinazolines
US7160890B2 (en) * 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
GB0002666D0 (en) * 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
DE60201921T2 (de) * 2001-01-24 2005-10-06 Yung Shin Pharmaceutical Ind. Co., Ltd. Kondensierte Pyrazolverbindungen
US20050089473A1 (en) * 2003-09-10 2005-04-28 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001502318A (ja) * 1996-10-14 2001-02-20 バイエル・アクチエンゲゼルシヤフト 心臓血管系および中枢神経系の特定疾病を治療するための縮合（ヘタリール置換）１―ベンジル―３―ピラゾール誘導体の使用
JPH11302277A (ja) * 1997-10-06 1999-11-02 Hoechst Marion Roussel Deutsche Gmbh ピラゾール誘導体、その製法および医薬としてのその使用
WO2001016359A2 (en) * 1999-08-31 2001-03-08 University College London Screen for axon viability
WO2001049275A2 (en) * 1999-12-29 2001-07-12 Queen's University At Kingston Methods and compositions for mitigating pain using nitrate esters
WO2002010137A2 (en) * 2000-07-31 2002-02-07 Signal Pharmaceuticals, Inc. Indazole derivatives as jnk inhibitors
WO2002083648A1 (fr) * 2001-04-16 2002-10-24 Eisai Co., Ltd. Nouveau compose a base de 1h-indazole
WO2003024397A2 (en) * 2001-09-14 2003-03-27 Carlsbad Technology, Inc. Enhancement of learning and memory and treatment of amnesia
WO2003068754A1 (en) * 2002-02-13 2003-08-21 Astrazeneca Ab Therapeutic substituted indazole derivatives

Also Published As

Publication number Publication date
DE602004025885D1 (de) 2010-04-22
US20040077702A1 (en) 2004-04-22
TW200510329A (en) 2005-03-16
KR20050024272A (ko) 2005-03-10
EP1512400A1 (en) 2005-03-09
CN1626077A (zh) 2005-06-15
EP1512400B1 (en) 2010-03-10
ATE460161T1 (de) 2010-03-15

Similar Documents

Publication Publication Date Title
CN108524482B (zh) 2-(取代苯氨基)苯甲酸类fto抑制剂治疗白血病的用途
CN103119047B (zh) 三环类蛋白酶体活性增强化合物
US9822058B2 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP6989505B2 (ja) Ｍａｌｔ１阻害剤およびその使用
JP5641054B2 (ja) 新規化合物、並びに、キネシンスピンドルタンパク質阻害剤及びその応用
WO2008074068A1 (en) Substituted quinoline derivatives as antiamyloidogeneic agents
US10501433B2 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CN107151250B (zh) 嘧啶类七元环化合物、其制备方法、药用组合物及其应用
US9884853B2 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CN112714761A (zh) 用作分子伴侣介导的自噬调节剂的化合物
JP2005075834A (ja) 神経変性疾患の処置
JP2005527518A (ja) 新規なカルコン（ｃｈａｌｃｏｎｅ）誘導体とその使用
CN113214097B (zh) 治疗阿尔茨海默病的化合物
CN107141287B (zh) 2-亚胺-5-酮基-2,5-二氢-1-h-二吡啶并嘧啶类化合物
AU2019385480B2 (en) Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders
CN101730565B (zh) 取代膦酸酯及其用于减少淀粉样聚集物的用途
CN109602734A (zh) 用于治疗白血病的化合物和方法
RU2629929C2 (ru) 2β,3α,5α-ТРИГИДРОКСИ-АНДРОСТ-6-ОН, СПОСОБЫ ЕГО ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
JP2025003966A (ja) キノンレダクターゼ２阻害剤化合物およびその使用
JP2005502722A (ja) 学習及び記憶の亢進ならびに健忘症の治療
JP7382944B2 (ja) 神経変性疾患を予防・治療するための新規な化合物及びその応用
WO2007053650A2 (en) Diazonamide a analog
WO2025255550A1 (en) Flavone therapeutics
CN115558013A (zh) 一种甾体磷酸酯化合物及其应用
CN111727039A (zh) 大肠炎改善剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070831

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110215